Test Price
2,800 AED✅ Home Collection Available
RYR2 Gene NGS Test for Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1) in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Next-Generation Sequencing (NGS).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with genetic counseling.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The RYR2 gene NGS test analyzes the entire coding region of the ryanodine receptor 2 gene to identify pathogenic variants responsible for catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1), a life-threatening inherited arrhythmia disorder. This comprehensive DNA analysis enables accurate diagnosis, risk stratification, and cascade testing of family members who may also carry the familial variant.
| Feature | Our RYR2 NGS Test | Closest Alternative (Sanger Sequencing Single Gene) |
|---|---|---|
| Method | Next-Generation Sequencing (NGS) – Full Gene Coverage | Sanger Sequencing – Single Amplicon per Exon |
| Detection Rate | >99% of pathogenic variants including deep intronic & novel mutations | ~95% for known point mutations, may miss large rearrangements |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specializing in inherited cardiac conditions, I recognize the profound implications of identifying a pathogenic RYR2 variant. This test provides vital information for clinical management, but results must always be interpreted within the broader context of your personal and family medical history. Genetic counseling is an essential component of this process, ensuring patients fully understand the implications for themselves and their relatives.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
Do not discontinue prescribed antiarrhythmic medications, beta-blockers, or any cardiac therapy without direct consultation with your managing cardiologist. Abrupt cessation may trigger life-threatening arrhythmias, especially during physical exertion or emotional stress. Always maintain a current medication list accessible to emergency medical personnel.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Asymptomatic minors without prior cardiologist evaluation; active infection or febrile illness; inability to provide informed consent for genetic testing.
- ER Red Flags: Syncope (fainting) during exercise or emotional stress; seizure-like activity; rapid palpitations with chest pain; sudden cardiac arrest in a first-degree relative.
Patient FAQ & Clinical Guidance
1. What is the RYR2 gene test for CPVT1?
The RYR2 gene NGS test detects pathogenic variants causing catecholaminergic polymorphic ventricular tachycardia type 1, an inherited arrhythmia disorder. This comprehensive DNA analysis examines the entire RYR2 gene to identify mutations responsible for CPVT1, enabling accurate diagnosis, risk stratification, and cascade testing of family members. CPVT1 typically presents in childhood or adolescence with stress-induced syncope and carries a risk of sudden cardiac death if untreated.
2. How is the test performed and what sample is needed?
The test requires a standard EDTA whole blood sample collected via routine venipuncture. A finger-prick blood spot on a DNA FTA card is also acceptable for pediatric patients or remote collection. Our VIP Mobile Phlebotomy service provides hospital-grade collection at your residence with temperature-controlled cold-chain transport to the laboratory. No fasting is required, and pre-test hydration is encouraged to facilitate venous access.
3. What do positive and negative results mean?
A positive result confirms a genetic predisposition to CPVT1, guiding tailored beta-blocker therapy and consideration of implantable cardioverter-defibrillator (ICD) placement. It also enables cascade testing in at-risk relatives. A negative result reduces the likelihood of RYR2-mediated CPVT1 but does not eliminate the diagnosis, particularly if strong clinical suspicion exists. Broader genetic panels for inherited arrhythmias may be recommended. All results include a telephonic consultation with a genetic counselor to review implications.
4. What is the turnaround time and how do I receive results?
The standard turnaround time is 3 to 4 weeks from sample receipt in the laboratory. Results are delivered via a secure patient portal and accompanied by a detailed clinical report interpretable by your cardiologist or genetic specialist. A telephonic post-test guidance session is scheduled within 5 business days of result release.
UAE Regulatory & Data Privacy Adherence
Your genetic data is protected under UAE law. All testing and data handling comply with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of genomic and health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating electronic health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring patient safety, informed consent, and clinical accountability in genetic testing.
DNA Labs UAE holds full DHA facility licensure and ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139). All patient data is encrypted and access-restricted in accordance with international genomic data security standards.
Clinical & Logistical Metadata
| Test Name | RYR2 Gene NGS Test for Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Coding Region & Splice Sites |
| ICD-10-CM Code | I47.2 (Ventricular tachycardia) |
| LOINC Code | 81395-2 (RYR2 gene targeted mutation analysis) |
| DHA Facility License & Address | DNA Labs UAE – DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians